18 and older, any sex, with Clostridium Difficile Infection. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of StoolPrimary· day 10-13
The number and percentage of patients who achieved at least 2 log10 colony forming units (CFU)/g of stool reductions of Clostridium difficile spores from baseline by the end of therapy (days 10-13).
Group
Value
95% CI
Fidaxomicin
11
Vancomycin
6
C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of StoolPrimary· day 10-13
The number and percentage of patients who achieved at least 2 log10 CFU/g of stool reductions of Clostridium difficile vegetative cells from baseline by the end of therapy (days 10-13)
Group
Value
95% CI
Fidaxomicin
4
Vancomycin
5
Sponsor's own description
The purpose of this study is to compare number of vegetative cells and spores in stool over time for fidaxomicin or vancomycin in patients diagnosed with their first episode of C. difficile infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07435051 — Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cie
· Phase 3
· not yet recruiting
NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
· Phase 4
· not yet recruiting
NCT06702345 — Clostridioides Difficile Controlled Human Infection Model
· NA
· not yet recruiting
NCT06716749 — Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty
· Phase 2
· completed
NCT06439953 — Irrisept Solution for Instrumented Spine Surgery
· NA
· recruiting
Other recruiting trials for Clostridium Difficile Infection
Currently open trials in the same condition.
NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
· Phase 2, PHASE3
· recruiting
NCT06703918 — Study on Clostridium Difficile Infection in Infants
· recruiting
NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
· Phase 2
· recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation
· NA
· recruiting
NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
· NA
· recruiting
Other Hartford Hospital trials
Trials by the same sponsor.
NCT04855526 — THC + CBD and Memory Study
· EARLY_PHASE1
· not yet recruiting
NCT06484621 — Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery
· NA
· recruiting
NCT06481436 — Use of Artificial Intelligence by Urogynecologic Patients
· NA
· active not recruiting
NCT06329518 — Rezafungin Pharmacokinetics in Patients on ECMO
· Phase 1
· withdrawn
NCT06123702 — Cannabidiol Effects on Fear Extinction in Social Phobia
· EARLY_PHASE1
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hartford Hospital
Last refreshed: 28 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01818141.